Education & Credentials
University of Arizona
University of California, Los Angeles
University of California, Irvine
Obstetrics and Gynecology and Gynecologic Oncology
- MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
- Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice
- Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
In The Media
- Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee
- Arizona Oncology Plays Pivotal Role in Securing FDA Approval of Zejula (Niraparib) for Treatment in Advanced Ovarian Cancer
- OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer
- McKesson Specialty Health Selected by TESARO to provide ZEJULATM (niraparib), Approved for the Treat
- Arizona Oncology Adds Four Gynecologic Oncologists, Expanding World-Class Gynecologic Cancer Service
Dr. Bradley Monk graduated at the top of his class from the University of Arizona College of Medicine-Tucson in 1988, and completed a residency in Obstetrics and Gynecology at the University of California, Los Angeles, in 1992. Between 1988 and 1995, he was the recipient of three fellowships in Medical Genetics and Gynecologic Oncology. In 1995, Dr. Monk was appointed director of gynecologic oncology at Texas Tech University Health Services Center and, from 1998 until 2010, was associate professor with tenure of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and director of research in the Department of Obstetrics and Gynecology. Dr. Monk was then appointed director and professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. In 2016, he became a member of Arizona Oncology and part of the US Oncology Network and continues to practice in Phoenix. Most recently, he has been appointed the US Oncology medical director of gynecologic oncology research. Dr. Monk is also a professor on the clinical scholar track at the University of Arizona College of Medicine – Phoenix and works at Arizona Oncology (US Oncology Network). He has been named one of Arizona’s “Top Doctors” by PHOENIX magazine 5 years in a row beginning in 2012.
Dr. Monk’s research interests include the prevention and treatment of gynecologic cancers. He was the first to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian cancer, and his papers in the New England Journal of Medicine led to the global approval of anti-VEGF therapy and PARP inhibitors in recurrent ovarian and cervical cancers in 2014. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Dr. Monk was also awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer, is on the board of directors for the GOG Foundation, Inc., and is the cervical cancer chair for for the Gynecologic Cancer Intergroup (GCIG). He is past president of the Western Association of Gynecologic Oncologists (WAGO) and current co-director for the GOG Research Consortium (GOG-Partners).
Dr. Monk is a fellow of the American College of Surgeons (ACS), the American College of Obstetricians and Gynecologists (ACOG), and the American Society for Colposcopy and Cervical Pathology (ASCCP), as well as being an active member of the Society of Gynecologic Oncology (SGO), American Society of Clinical Oncology (ASCO) and other professional organizations. He has authored more than 300 peer-reviewed articles along with 31 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.
Dr. Monk has been an advocate of holistic medicine for almost three decades. He championed studying quality of life (QOL) within the Gynecologic Oncology Group when he was appointed the first QOL co-principal investigator for a phase III ovarian cancer clinical trial in 1994. He has published and lectured extensively on this around the globe. Dr. Monk frequently uses nutrition, physical activity, and mind-body techniques to promote healing and wellness. Together with control of the cancer and enhanced QOL, his patients thrive.